Previous 10 | Next 10 |
Company provides 2020 product revenue guidance range of $89 million to $93 million representing growth of approximately 20% to 25% over preliminary 2019 full year results Cerus Corporation (Nasdaq:CERS) announced today preliminary product revenue for the fourth quarter and full year 20...
New Five-Year Agreement Maintains Exclusive Use of INTERCEPT Platelets and Expands Use of INTERCEPT Plasma Cerus Corporation (Nasdaq:CERS) announced today that it has signed a new five-year commercial contract with Swiss Transfusion SRC, a company of the Swiss Red Cross, for purchase o...
Cerus Corporation (Nasdaq:CERS) announced today that Kevin D. Green, Cerus’ chief financial officer, will present at the Stifel 2019 Healthcare Conference on Tuesday, November 19, 2019 at 2:25 p.m. ET in New York City. A live webcast of the presentation will be available on the Inv...
Alnylam Pharmaceuticals (NASDAQ: ALNY ) initiated with Buy rating and $110 (21% upside) price target at BofA Merrill Lynch. More news on: Alnylam Pharmaceuticals, Inc., Arena Pharmaceuticals, Inc., National Vision Holdings, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
Cerus Corp ( CERS ) recently announced their Q3 earnings with a slight miss on EPS and a solid beat on revenue. Although investors should be encouraged by the company’s third-quarter performance, it is the FDA’s final guidance concerning platelet storage and transfusions that...
Historically, buying small-cap stocks into year-end has been savvy because of the "January Effect", a period of strong excess performance by small-cap stocks that stretches from mid-December through the following May. Over the past decade, the median return of the iShares Russell 2000 ETF (I...
Cerus Corporation (Nasdaq:CERS) announced today that Kevin D. Green, Cerus’ chief financial officer, will present at the Stephens Nashville Investment Conference on Wednesday, November 13, 2019 at 10:30 a.m. CT. A live webcast of the presentation will be available on the Investor R...
Cerus Corporation (CERS) Q3 2019 Earnings Conference Call October 30, 2019 4:30 PM ET Company Participants Tim Lee – Investor Relations Obi Greenman – President and Chief Executive Officer Laurence Corash – Co-Founder and Chief Scientific Officer Vivek Jaya...
Image source: The Motley Fool. Cerus Corporation (NASDAQ: CERS) Q3 2019 Earnings Call Oct 30, 2019 , 4:30 p.m. ET Operator Continue reading
Cerus (NASDAQ: CERS ): Q3 GAAP EPS of -$0.13 misses by $0.01 . More news on: Cerus Corporation, Earnings news and commentary, Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Cerus Corporation (Nasdaq: CERS) announced today that its second quarter 2024 financial results will be released on Thursday, August 1, 2024, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discu...
Cerus Corporation (Nasdaq: CERS) today announced the appointment of Dean Gregory to its Board of Directors. Mr. Gregory has a 30+-year career as a leader in the global blood transfusion and cell therapy industry, with broad experience across commercialization, product development, supply chain an...
Symposium and Abstracts Highlight Data from Real-world Implementation and Utilization of INTERCEPT Platelets and Plasma as well as from Red Blood Cell and LED Illuminator Programs Cerus Corporation (Nasdaq:CERS) today announced a lunch symposium and selection of abstracts at the 38 th...